



Published in final edited form as:

*J Med Chem.* 2005 August 25; 48(17): 5437–5447. doi:10.1021/jm049050v.

## A Combination of Docking, QM/MM Methods, and MD Simulation for Binding Affinity Estimation of Metalloprotein Ligands

Akash Khandelwal<sup>1</sup>, Viera Lukacova<sup>1</sup>, Dogan Comez<sup>2</sup>, Daniel M. Kroll<sup>3</sup>, Soumyendu Raha<sup>4</sup>, and Stefan Balaz<sup>1,\*</sup>

<sup>1</sup>Department of Pharmaceutical Sciences and Center for Protease Research, North Dakota State University, Fargo, ND 58105, USA

<sup>2</sup>Department of Mathematics, North Dakota State University, Fargo, ND 58105, USA

<sup>3</sup>Department of Physics, North Dakota State University, Fargo, ND 58105, USA

<sup>4</sup>Department of Computer Science, North Dakota State University, Fargo, ND 58105, USA

### Abstract

To alleviate the problems in the receptor-based design of metalloprotein ligands due to inadequacies in the force-field description of coordination bonds, a four-tier approach was devised. Representative ligand-metalloprotein interaction energies are obtained by subsequent application of (1) docking with metal-binding-guided selection of modes; (2) optimization of the ligand-metalloprotein complex geometry by combined quantum mechanics and molecular mechanics (QM/MM) methods; (3) conformational sampling of the complex with constrained metal bonds by force-field based molecular dynamics (MD); and (4) a single point QM/MM energy calculation for the time-averaged structures. The QM/MM interaction energies are, in a linear combination with the desolvation-characterizing changes in the solvent-accessible surface areas, correlated with experimental data. The approach was applied to structural correlation of published binding free energies of a diverse set of 28 hydroxamate inhibitors to zinc-dependent matrix metalloproteinase 9 (MMP-9). Inclusion of step 3 and step 4 significantly improved both correlation and prediction. The two descriptors explained 90% of variance in inhibition constants of all 28 inhibitors, ranging from 0.08 to 349 nM, with the average unassigned error of 0.318 log units. The structural and energetic information obtained from the time-averaged MD simulation results helped understand the differences in binding modes of related compounds.

### Keywords

molecular dynamics - MD; QM/MM; docking; linear response approximation; binding affinity; free energy of binding; matrix metalloproteinases; metalloproteins

### Introduction

Metalloproteins play important roles in physiological processes (hemoglobin, cytochrome oxidase, catalase and superoxide dismutase), the receptor binding of potential drugs (carbonic anhydrases, matrix metalloproteinases, thermolysin, leucine aminopeptidase, phospholipase C, carboxypeptidase A and B, adenosine and cytidine deaminase), and drug metabolism (cytochromes P450 and methane monooxygenase), to give just a few examples.<sup>1–3</sup> In drug

CORRESPONDING AUTHOR FOOTNOTE: Stefan Balaz, North Dakota State University, College of Pharmacy, Sudro Hall Rm 8, Fargo, ND-58105; phone 701-231-7749; fax 701-231-8333; e-mail stefan.balaz@ndsu.edu.

design, a description of the ligand interactions with transition metals poses a challenge due to the possibility of multi-dentate coordination bonding that is most appropriately treated at the quantum mechanical level.<sup>4-11</sup> This study presents an approach to a receptor-based estimation of binding affinities of metalloprotein ligands that is more reliable than standard ensemble-based techniques at the expense of a modest increase in the computing time.

The fastest and usually least precise descriptions of coordination bonds are obtained using molecular mechanical approaches. Several techniques are available with varying levels of sophistication. The nonbonded approach<sup>12,13</sup> uses optimized electrostatics and van der Waals terms,<sup>14,15</sup> occasionally using dummy cations placed around the metal atom<sup>16,17</sup> to enforce the correct coordination geometry. The geometry enforcement is more stringent in the bonded model<sup>18-20</sup> that utilizes the bond terms including bond stretching, angle bending, and torsional terms. These approaches require a predefined valence of the coordinating metal, in contrast to the directional force field YETI that is more flexible in selection of appropriate valence.<sup>21,22</sup> Further force-field enhancements include addition of polarizable bonds,<sup>23,24</sup> directionality based on orbital hybridization,<sup>25</sup> and ligand field stabilization energy.<sup>26,27</sup> Unfortunately, the more sophisticated force fields are not readily available for a routine use in modeling of ligand-metal interactions.

Combined quantum mechanical and molecular mechanical (QM/MM) methods represent an economical approach to characterization of macromolecular processes that include changes in the covalent bond status.<sup>28-31</sup> The atoms directly involved in the chemical steps are typically included in the QM region, whereas the rest of the system is treated at the MM level. Initially developed for gas-phase calculations,<sup>32</sup> the QM/MM approach was first applied to enzyme systems by Warshel & Levitt.<sup>28</sup> QM/MM methods combine the efficiency of MM allowing for free energy simulations of macromolecules, with the accuracy and a systematic improvement potential provided by QM.<sup>33</sup> The methods have been implemented in combination with semi empirical and ab initio molecular orbital theory and with density functional theory (DFT). QM/MM-based molecular dynamics (MD) simulations have been used for modeling of enzymatic reactions,<sup>31,34,35</sup> but are computationally intensive and currently impractical for the prediction of binding affinities of a series of metalloprotein ligands. Alternatively, a large system as a whole can be treated at the QM level by fragmenting, linearly scaling approaches;<sup>36</sup> however, the QM/MM treatment seems to provide a better focus by applying the most sophisticated methods to the key chemical steps and the fast methods to the less important noncovalent processes.

Several categories of the methods for prediction of binding affinities to the receptors with known structures are available. Free Energy Perturbation (FEP),<sup>37</sup> Thermodynamic Integration,<sup>38</sup> and similar techniques<sup>39</sup> are the most sophisticated tools for free energy calculations. Extensive sampling resulting in extreme demands on computational resources and limitation to close homologs currently preclude their routine use in drug design. Computational costs can be reduced by partitioning of the binding energy into individual contributions and, in further simplification, by replacing the ensembles of structures generated in molecular simulations by single structures.

In ensemble-based partitioning approaches, only two states need to be considered: complexes and free interaction partners. The approaches in this category can be classified according to the use of adjustable parameters in the final relation between the binding affinity and the calculated free energy contributions. The MM-PBSA<sup>40,41</sup> and MM-GBSA<sup>42</sup> methods form the parameter-free category while the Linear Response (LR, a.k.a. Linear Interaction Energy) method<sup>43-45</sup> and its extended version (ELR)<sup>46-48</sup> represent the parametrized category. The contributions to the binding free energy are expressed as the differences  $\Delta$  between the solvated

ligand in the bound and free states in the ensemble averages (denoted by angle brackets) of respective quantities.

In ELR type methods, binding free energy  $\Delta G_b$  is calculated as the linear combination of the differences  $\Delta$  in the van der Waals energies, electrostatic energies,<sup>43-45</sup> and the solvent-accessible surface areas<sup>46-48</sup> (SASA) obtained from MD or Monte Carlo simulations:

$$\Delta G_b = \alpha \times \Delta \langle E_{vdw} \rangle + \beta \times \Delta \langle E_{el} \rangle + \gamma \times \Delta \langle SASA \rangle + \kappa. \quad (1)$$

The adjustable parameters  $\alpha$ ,  $\beta$ , and  $\gamma$  contain the protein-solvent and solvent-solvent interactions.<sup>49-51</sup> The van der Waals parameter  $\alpha$  depends on the used force field, as was shown e.g. for thrombin.<sup>47,49,52</sup> Its magnitude was analyzed with respect to hydrophobicity of the binding site.<sup>49</sup> The coulombic scaling coefficient  $\beta$  varies with the ligand nature and ligand surroundings (protein or water),<sup>53-55</sup> although its equality to  $1/2$  was assumed initially based on the linear response of the surroundings to electric fields.<sup>43-45</sup> Similar method for treatment of hydration of more complex molecules<sup>56</sup> required the use H-bond donor and acceptor counts, in addition to the quantities present in Eq. 1. Continuing studies of more diverse ligands may reveal the need for further empirical corrections.

Single-structure-based partitioning approaches, represented by VALIDATE,<sup>57</sup> the Free Energy Force Field approach,<sup>58,59</sup> COMBINE analysis,<sup>60</sup> and a single-structure version of the LR method using continuum electrostatics,<sup>61</sup> replace the ensemble averages by a single configuration, usually obtained by a direct geometry optimization of the receptor-ligand complex. Scoring functions are simplified single-structure-based partitioning approaches that are categorized as force field-based methods,<sup>62,63</sup> empirical free energy scoring functions,<sup>64-66</sup> and knowledge-based scoring functions.<sup>67-69</sup> They are mainly used in high-throughput virtual screening, in connection with fast docking procedures.

To overcome the limitations of the aforementioned methods in prediction of binding affinities to metalloproteins due to the difficulties in handling the transition metal atoms, we have combined docking, QM/MM calculations, and force-field-based MD methods into a coherent approach. The approach is tested using inhibitors of matrix metalloproteinases (MMPs),<sup>70</sup> which belong to the most-studied metalloenzymes. Development of MMP inhibitors is complicated by structural relatedness of the MMP family,<sup>71</sup> in which some members assume normal physiological roles and others are pathological, depending upon given concentration or activity.

## Results and Discussion

Interactions of metalloproteins with ligands are often difficult to describe effectively due to the limited availability of appropriate force fields. To predict binding affinities in these cases, we devised a four-tier procedure consisting of: (1) docking with the selection of poses based upon appropriate metal binding; (2) QM/MM optimization of the best docked geometries; (3) MD simulation with the metal binding group of the ligand confined in the geometry from Step 2; and (4) QM/MM single point interaction energy calculation based on the time-averaged structures from Step 3:

$$\Delta \langle E_{QM/MM} \rangle = \langle E_{QM/MM}^{\text{complex}} \rangle - \langle E_{QM/MM}^{\text{ligand}} \rangle - \langle E_{QM/MM}^{\text{receptor}} \rangle. \quad (2)$$

The QM/MM interaction energies are correlated in an ELR-type approach, along with SASA crudely parametrizing desolvation, with experimental affinities. The use of the energies of the

time-averaged structures in place of the ensemble averages of energies was previously shown to provide equivalent results in a parametrized partitioning approach to binding affinity correlations<sup>72</sup> and in protein  $pK_a$  prediction.<sup>73</sup> The approach was tested using published data<sup>70</sup> on inhibition of 28 hydroxamate inhibitors of MMP-9 (Table 1).

### Step 1 - Docking

Docking of the inhibitors to the MMP-9 structure taken from the Protein Data Bank<sup>74</sup> (PDB file 1GKC) was performed using FlexX.<sup>64,75</sup> The ranking of poses was based upon the distance between catalytic zinc and both hydroxamate oxygens in the interval 1.5 – 2.5 Å as the primary criterion and the FlexX score as the secondary criterion.<sup>76</sup> Docking provided a greater variety of the initial binding modes than superposition of the ligands with the ligand in the PDB file of the complex.<sup>77</sup> Since the MD simulations routinely do not sample conformations too different from the starting conformations, this step was instrumental in selecting the binding mode explaining the experimental data for several compounds. To reduce the QM/MM convergence time, for the top complexes of each ligand, the mobile region within 5 Å of the ligand superposition was briefly optimized by the conjugate gradient minimization using OPLS-AA force field.

### Step 2 - QM/MM Geometry Optimization

The charges and inter-atomic distances for all 28 ligands (Table 1) do not differ much; therefore we present them as average values in Figure 1. The maximum standard deviations were 8.1 % for charges and 2.5 % for distances. Charge transfer from hydroxamate group to zinc is significant, albeit very similar for all studied compounds (Figure 1). For the free/bound hydroxamates, the average bond lengths were (in Å): C=O 1.236/1.284, C-N 1.355/1.308, N–O 1.401/1.364, and O–H 0.982/1.590, respectively. In the QM/MM geometry optimization of the complex, the proton from the hydroxamate OH group was transferred to the Glu402 oxygen but remained H-bonded to the parent oxygen. The average C=O, C-N and N-O bond lengths for the bound state obtained here (1.284, 1.308 and 1.364 Å) are closer to deprotonated Zn-coordinated hydroxamate (1.294, 1.317 and 1.378 Å) than to neutral hydroxamate with respective distances of 1.279, 1.337 and 1.416 Å.<sup>78</sup> The distance between Glu402 oxygen and oxygen of the reverse hydroxamate (2.70 Å) in MMP-9 and hydroxamate oxygen in MMP-779 and MMP-880·81 (2.6–2.8 Å) complex are in close agreement with the distance found in Step 2 (2.604 Å). These facts suggest that bound hydroxamate structure is, in the presence of proton-accepting Glu402, closer to deprotonated state than to neutral form. Hydroxamates approach the binding site as neutral molecules ( $pK_a \geq 8.9$  for the studied compounds)<sup>82</sup> and require ionized Glu402 for full potency.<sup>83</sup>

Two hydroxamate oxygens may bind to zinc in monodentate or bidentate configurations that result in four- or five-fold coordination, respectively. Among the structures of hydroxamates bound to MMPs in PDB, the bidentate zinc binding prevails, with trigonal bipyramidal (TB) configurations occurring about six times more frequently than the square-based pyramid (SP). After QM/MM optimization, the bidentate TB coordination was observed in the studied hydroxamate structures, as evidenced by the average geometries of all 28 complexes (Figure 1). The bond lengths of the two Zn-O bonds (Zn-O1 and Zn-O2) are  $2.029 \pm 0.018$  Å and  $2.089 \pm 0.012$  Å, respectively, which indicates that the two oxygens coordinate with zinc about equally. The average bond angles O1-Zn-N in His401, His405 and His411 in these complexes are  $121.77 \pm 14.81^\circ$ ,  $135.58 \pm 8.95^\circ$ , and  $82.06 \pm 1.65^\circ$ , respectively (ideal values for TB:  $120^\circ$ ,  $120^\circ$ ,  $90^\circ$ ; and for SP:  $90^\circ$ ,  $180^\circ$ ,  $90^\circ$ ). The average bond angles O2-Zn-N in the same order are  $101.55 \pm 1.89^\circ$ ,  $95.07 \pm 2.13^\circ$ , and  $155.23 \pm 2.98^\circ$ , respectively (both TB and SP:  $90^\circ$ ,  $90^\circ$ ,  $180^\circ$ ). The average bond angle of O2-Zn-O1 is  $79.66 \pm 0.61^\circ$ , approaching the ideal value of  $90^\circ$  for both TB and SP configurations.

The QM/MM approach for the entire binding domain provided a more realistic picture than the studies using reduced systems<sup>5,10,78,84,85</sup> that do not consider the protein surroundings of bound ligands. In this case, ionized Glu402 is crucial for a correct description of binding. The QM/MM approach handled the zinc-ligand charge transfer,<sup>36</sup> bond length changes, polarization, and ionization<sup>25</sup> upon binding to zinc, which would be difficult to describe by advanced force fields.<sup>21–27</sup> Albeit very similar in the studied set, the electronic phenomena can be anticipated to play a more important role in a heterogeneous series of ligands.

### Step 3 - MD Simulations

The QM/MM optimized complexes were subjected to the MD simulation with the constrained zinc-hydroxamate oxygens bond lengths and angles, to obtain conformational sampling for the rest of the complex. To reduce the computational expense, only one MD simulation, for the enzyme-inhibitor complex, was performed.<sup>41</sup> The energy terms for the enzyme and inhibitor taken from the MD simulation for the complex were comparable to those obtained from running separate simulations for the enzyme and inhibitor, as checked for several inhibitors. Inspection of the trajectories revealed that the secondary and tertiary structure of the ligand-receptor complex remained stable during the entire 200-ps simulation period (data not shown). The influence of zinc bond constrains on movement of other ligand parts is illustrated in Figure 2. The chiral carbon (Table 1) that is only 2–3 bonds apart from the constrained hydroxamate oxygens is comparatively rigid. The ring nitrogen and phosphorus are separated by 1–2 more bonds from the constrained part and exhibit amplitudes comparable to those of distant binding site parts like the oxygen of Glu402 that is H-bonded to hydroxamate oxygen. The ensemble averages of the van der Waals and electrostatic energies that were calculated for the time-averaged structures obtained after 5 ps simulations are listed in Table 1. Longer simulation times provided similar samplings that did not improve the correlations using Eq. 1 and Eq. 3 and the results are not shown. The  $\Delta$ SASA terms were lower for the time-averaged structures from Step 3 than for the minimized structures from Step 2 in 16 cases (Table 1). For 12 ligands, however, the  $\Delta$ SASA terms increased, indicating that MD sampling found better binding modes than minimization. The largest increases were observed for ligands **3, 5, 6, 8, 20, 22, 25, and 26**.

### Step 4 - Calculation of QM/MM Interaction Energies

For the time-averaged structures resulting from 5-ps MD simulations, single point QM/MM interaction energies were calculated according to Eq. 2 and are summarized in Table 1. The time-averaged structures were used to preserve conformational sampling obtained in Step 3 that should result in more realistic descriptions than using the single optimized structures.<sup>61</sup> As can be expected, the QM/MM energy changes are much smaller for the time-averaged structures from Step 3 than for the minimized structures in Step 2. The QM/MM calculations properly treat the coordination bonds between zinc and the ligands. Therefore, the QM/MM interaction energies are expected to provide better energy estimates than the MM-based force field simulations.

### Correlations with Inhibitory Activities

The QM/MM energies, along with SASA characterizing ligand desolvation, were correlated with experimental binding affinities using Eq. 3, in a way reminiscent of the ELR approach (Eq. 1):

$$\Delta G_b = \alpha \times \Delta \langle E_{\text{QM/MM}} \rangle + \gamma \times \Delta \langle \text{SASA} \rangle + \kappa \quad (3)$$

For a comparison, the MD results were correlated with biological data using Eq. 1. The influence of the SASA's polar and nonpolar components, as well as that of the constant term  $\kappa$  were examined. The resulting equations are not listed because they improved neither correlations nor predictions.

The fits of Eq. 1 and Eq. 3, with  $\log K_i$  on the left side, to the inhibition data for the 28 compounds for individual Steps are summarized in Table 2. Prediction of the MMP-9 inhibition constant based upon the linear correlation of the experimental data with the FlexX scores in Step 1 resulted in a poor correlation characterized by  $r^2 = 0.044$ , with  $r$  being the correlation coefficient.

The QM/MM energies of the ligand-enzyme complexes with optimized geometries, obtained in Step 2, resulted in a slightly improved statistics ( $r^2 = 0.504$ , Table 2). The correlation is dominated by the SASA term. Inclusion of the QM/MM energy for the optimized geometry did not improve the correlation. The pertinent regression parameter  $\alpha$  has a negative sign and an inflated error, possibly due to a moderate cross-correlation between the QM/MM energy and the SASA term ( $r^2=0.460$ ).

The use of the energy terms from the MD conformational sampling in Step 3 pushed the correlation to  $r^2=0.764$  (Table 2). Compounds **3**, **7**, **20**, **22**, and **26** (Table 1) that saw the greatest description improvement in Step 3 (0.6 – 1.1 log units), exhibit a significant change in the conformation of the bound ligand upon MD sampling. The change in the binding conformation is accompanied by a large increase of  $\Delta$ SASA, except compound **7**. Descriptions for other compounds with  $\Delta$ SASA increased upon MD sampling (**5**, **6**, **8**, and **25**, Table 1) improved by 0.1 – 0.3 log units. For the van der Waals coefficient  $\alpha$ , the error is almost equal to the parameter estimate, while for the coulombic coefficient  $\beta$ , the sign of the parameter estimate is negative and the error term larger than the parameter estimate. This misbehavior may be caused by the collinearity problem of the van der Waals and electrostatic terms ( $r^2=0.712 - 0.839$  for different simulation times). The low value of the van der Waals coefficient  $\alpha$  might indicate a low hydrophobicity of the MMP9 binding site, if the results of the original analysis<sup>49</sup> are also valid for correlations with the explicit SASA term. Cross-correlation of van der Waals and SASA terms was very weak ( $r^2=0.174$ ).

The best model for Step 4 contained just the single point QM/MM energy for the time-averaged structures and the SASA term and was obtained using the data from a 5-ps MD simulation. This treatment was most beneficial for compounds **18** and **19**, the residuals of which decreased from  $\sim 1.0$  in Step 3 to  $\sim 0.3$  log units in Step 4, and compounds **5** and **8**, with residuals improving from  $\sim 0.6$  to  $\sim 0.1$  log units. The correlation for all 28 compounds is characterized by  $r^2 = 0.900$  and the standard deviation  $SD = 0.318$  reflecting a good agreement between actual and calculated values (Table 2). For each parameter, the probability  $>F$  ratio was  $<0.0001$ , implying that the likelihood of a random occurrence of a significant parameter is negligible. The cross-correlation between the QM/MM energy and SASA is very weak as indicated by the  $r^2$  value of 0.140. The dominance of the SASA terms, clearly seen in Table 2, is probably reflecting the effect of burial of the inhibitor in the binding site. This phenomenon was described previously in the analysis of binding energies of several ligand-protein complexes.<sup>86</sup> A plot of experimental activity as a linear combination of contributions from QM/MM energy and SASA is shown in Figure 3. The quality of correlations in Step 4 remained at about the same level with the increase in the MD simulation time for obtaining the time-averaged structures. Consequently, the simulation time of 5 ps seems to be sufficient for the binding energy analyses in the studied case, which is characteristic by constrained geometry of the zinc binding group in the complex and rigid protein structure outside the 5-Å region around the ligand superposition.

The adjustable parameter  $\kappa$  in Eq. 3 yields an attractive term of about  $-2.623$  log units (Table 2), providing a base value for the inhibitors that is then modulated by the QM/MM interaction and SASA terms. The values of the QM/MM terms (Table 1) are negative and the associated positive coefficient (Table 2) implies that a strong interaction between the inhibitor and the binding site is important for inhibition. The SASA terms (Table 1) are negative, implying burial of the surface area upon binding. The associated parameter  $\gamma$  (Table 2) is positive so that the removal of mostly hydrophobic surface area from the contact with water upon binding promotes the binding, which simply reflects the hydrophobic effect.<sup>87</sup> The obtained values of  $\gamma$  (Table 2:  $0.00754$ - $0.011 \text{ \AA}^{-2}$ ; multiplied by  $R \times T \times \ln 10 = 1.419 \text{ kcal/mol}$  to account for the change of the dependent variable from free energy to  $\log K_i$  as described in part Methods/Data Set) are in the same range as the slopes of the linear dependencies of solvation free energies on SASA:  $0.007 \text{ kcal}/(\text{mol} \times \text{\AA}^2)$  for alkanes,<sup>88</sup> and  $0.016$ <sup>89</sup> or  $0.020 \text{ kcal}/(\text{mol} \times \text{\AA}^2)$ <sup>46</sup> for various compounds.

The robustness of the regression equations and their predictive abilities were probed by cross-validation. The leave-one-out (LOO) procedure and especially the leave-several-out (LSO) procedure with a random selection of 6-member test set that was repeated 200 times provided a thorough evaluation. The predictive root mean squared error (RMSE) for Eq 3 obtained for the 5 ps MD simulation time is the lowest among all correlations. The RMSE values using LOO (0.331) and LSO (0.319) were comparable to that of the RMSE of the whole data set (0.315). Inclusion of all Steps in the correlation was warranted by the improvement in descriptive and predictive ability. The quality of correlations for individual Steps is documented in Figure 4.

The correlation described by Eq. 3 with the optimized parameters given in Table 2 is much better than our previous ELR results<sup>77</sup> obtained from MD simulations with nonbonded zinc-ligand interactions. The predictive ability of the ELR model for all 28 compounds was characterized by RMSE from LSO cross-validation between 0.584 and 1.173, depending upon the simulation time (Table 6, model A in ref. 77). Comparison of these values with equivalent LSO RMSE values in the right-most column of Table 2 shows that current correlations were significantly better only for Step 4 (RMSE 0.319), where single-point QM/MM energies of the time-averaged structures were used. The results from MD simulations employing the same time-averaged structures (Step 3), although run with improved starting geometries of hydroxamate groups from the QM/MM minimization in Step 2, did not show any major progress: the best RMSE was 0.531 that is only slightly better than 0.584 resulting from a less constrained MD simulation. The QM/MM energy from the minimization procedure (Step 2) ended with the best RMSE of 0.751 that is not much better than RMSE of 0.785 that was obtained previously with a force-field minimization. Apparently, conformational sampling embodied in the time-averaged structures (Step 3) and a good description of the zinc coordination bonds (Step 4) are jointly required for a good correlation with experimental inhibitory potencies and none of these procedures alone is making a major breakthrough.

## Binding Trends

Eq. 3 and underlying structural information on bound ligands present a straightforward framework for understanding the trends in the observed activities. For a given series of hydroxamate derivatives in Table 1, the ranges for the contributions from QM/MM interactions and burial of solvent accessible surface area are  $451.81 \text{ kcal/mol}$  and  $305.97 \text{ \AA}^2$ , respectively. The SASA term contributes more to the computed activities than the QM/MM term. Representative binding modes of compound **22** (Table 1) obtained after FlexX docking, minimization, and MD simulation are illustrated in Figure 5. The differences between minimized structures and time-averaged structures after MD sampling in Step 3 were sometimes larger than those shown in Figure 5, especially for compounds **3**, **7**, **20**, and **26**

(Table 1). The S1 subsite is structurally defined by Asp185, Gly186, Leu187, Leu188, Ala189, His190, Ala191, and Phe192, while the S2' subsite is defined by Ala417, Leu418, Met419, Tyr420, Pro421, Met422, and Tyr423. The P=O group of all the ligands except **2**, **3**, **13**, **16**, **20**, and **25** forms hydrogen bonds with the backbone NH of Leu188. In general, the R<sub>1</sub> substituents occupy the pocket lined with residues of the S1 subsite while R<sub>2</sub> substituents occupy the S2' subsite (Figure 6). Even compounds with longer R<sub>2</sub> substituents (compounds **18–22**) leave an empty pocket in the S2' subsite. Since these are the most potent compounds in the given series, further lengthening of the R<sub>2</sub> substituents may be helpful in designing more potent inhibitors.

**The Effect of Stereoisomerism**—Compound **1** is a potent inhibitor ( $K_i = 5.05$  nM) while compound **2** exhibits only moderate activity ( $K_i = 349$  nM). The compounds are structurally similar except the configuration on C-3 where **1** exhibits the R-configuration while in **2** it is the S-configuration. The importance of the R-configuration at the  $\alpha$  carbon is well documented.<sup>90–94</sup> Binding modes after MD simulation (Step 3) of the two inhibitors are shown in Figure 7. The zinc-binding group is tightly bound to zinc in both the compounds but the rest of the ligand is flipped by 180°. In case of **1**, several hydrogen bonds can be discerned: between the oxygen atom of the ethyl ester group and the main chain NH of Leu188; between the hydroxamate OH and oxygen of Glu402 (and also an intramolecular H-bond with the phosphonamide oxygen). In contrast, compound **2** forms only one hydrogen bond with the Glu402 (Figure 7). The H-bond pattern is reflected in computed QM/MM interaction terms (Table 1) that are equal to  $-698.95$  kcal/mol for **1** and  $-489.14$  kcal/mol for **2**. Additional benefit for **1** comes from the burial of more SASA ( $-389.34$  Å<sup>2</sup>) than for **2** ( $-311.53$  Å<sup>2</sup>).

**The Role of 4-Methoxyphenyl in R<sub>2</sub> Position**—Substitution of 4-methoxyphenyl in the R<sub>2</sub> position in **1** with pyridine ring in **15** resulted in a severe loss of activity. The fact can be explained by the lower QM/MM energy values as well as a lower burial of SASA in **15** as compared to **1** (Table 1). Compounds **10–12** ( $K_i = 42.7$ ,  $41.8$ , and  $51.9$  nM, respectively) are structural analogs of compound **1** but exhibit lower activity as compared to **1** ( $K_i = 5.05$  nM). The 4-methoxyphenyl group in R<sub>2</sub> position of **1** is replaced with phenyl (**10**), 4-methylphenyl (**11**), and 4-fluorophenyl (**12**) substituents. Compounds **10–12** exhibit less burial of SASA and similar (**11**) or lower QM/MM energy values (**10** and **12**), as compared to **1** (Table 1).

**Interactions vs. SASA Burial**—Compound **19** (R<sub>2</sub>=Ph-Ph) differs from **20** (R<sub>2</sub>=Ph-O-Ph) in the interlinking oxygen atom and exhibits a lower activity. The ether linkage in **20** is expected to be better solvated in the unbound state of the ligand than in the bound state. However, this factor is not encoded in the overall  $\Delta$ SASA value: greater  $\Delta$ SASA ( $-604.77$  Å<sup>2</sup>) of **20** than **19** ( $-423.94$  Å<sup>2</sup>) merely reflects the size difference as both ligands bind in a similar way. Although the QM/MM energy term is more favorable for **19** ( $-940.95$  kcal/mol) than for **20** ( $-834.28$  kcal/mol), this contribution is negated by the dominance of the SASA term and consequently higher activity for compound **20**.

Compounds **20** and **21** differ in isosteric R<sub>2</sub> substituents (Ph-O-Ph and Ph-O-C<sub>6</sub>H<sub>5</sub>N, respectively). The QM/MM as well as SASA terms are more favorable for compound **20** as compared to compound **21** (Table 1). For compound **20**, MD simulation in Step 3 found a new time-averaged binding mode resulting in a substantial increase in  $\Delta$ SASA that explains higher activity of **20** as compared to **21**. In this mode, the P=O group of **20** forms H-bond interaction with backbone NH of Ala189 that was not observed after QM/MM minimization in Step 2.

MD simulation also found a new time-averaged binding mode for compound **26**, resulting in a significant increase in  $\Delta$ SASA and improvement in description of activity after Step 3 as compared to Step 2. A closer look at the structural changes shows that the new mode also exhibits a different H-bonding interaction pattern: the P=O group forms H-bond with backbone



NH of Leu188, while after Step 2 the NH group in X4 was H-bonded with the backbone C=O group of Gly186.

## Methods

### Data Set

Published inhibitory potencies, characterized by the inhibition constants  $K_i$  at 37 °C, of a series of 28 hydroxamate derivatives<sup>70</sup> towards MMP-9 were used (Table 1). The inhibition constants are the inverse values of the association constants  $K$ . The left sides of Eq. 1 and Eq. 3 are the binding free energies  $\Delta G_b = -R \times T \times \ln K = R \times T \times \ln 10 \times \log K_i$ . The  $\log K_i$  values were used as dependent variables, in order to work with the dependent variables that are most common in medicinal chemistry. The optimized values of adjustable parameters  $\alpha$ ,  $\beta$ ,  $\gamma$ , and  $\kappa$  (Table 2) can be recalculated for the  $\Delta G_b$  as independent variable by multiplication with  $R \times T \times \ln 10 = 1.419$  kcal/mol.

Coordinates of the MMP-9 catalytic domain were taken from the recently reported x-ray crystal structure of the MMP-9 in the complex with N-formyl-N-hydroxy-2-(2-methylpropyl)- $\beta$ -alanyl-N,3-dimethyl-L-valinamide, a 'reverse hydroxamate' inhibitor, as deposited in the PDB (file 1GKC).<sup>95</sup>

### Construction of Initial Inhibitor/Enzyme Complexes

Three-dimensional structures of ligands were constructed using the SYBYL6.9 suite of programs<sup>96</sup> running under Irix 6.5. Full geometry optimization and charges were calculated using DFT/B3LYP-6-31G\*\* approach.<sup>97</sup> The inhibitors were docked into the active site of MMP-9 using the FlexX program that considers ligand conformational flexibility by an incremental fragment placing technique.<sup>64,75</sup> For each ligand, the best conformation in the active site was selected from the top 30 poses generated by FlexX using the distances in the interval 1.5 – 2.5 Å between both hydroxamate oxygens and the catalytic zinc atom as the primary criterion and the FlexX ranking as the secondary criterion.<sup>76</sup> Step 1 was completed by a brief MM geometry optimization using the OPLS-AA force field with a distance-dependent dielectrics and conjugate gradient algorithm with a convergence criterion of 0.001 kcal/(mol $\times$ Å).

**QM/MM Calculations**<sup>98</sup> were used for three purposes: optimization of the initial geometries of the inhibitor-enzyme complexes and estimation of their interaction energies (Step 2), as well as estimation of the interaction energies for the time-averaged structures (Step 4) obtained by MD simulation (Step 3). The QM region consisted of side chains of His405 and His411, the backbone atoms and side chains of His401 and Glu402, the entire inhibitor, and the zinc ion. The backbone atoms were included to obtain valid QM/MM cuts. The rest of the protein was treated with MM. The protein and water outside 5 Å of the ligand superposition after Step 1 were frozen.

The interface between QM and MM regions is mediated by frozen orbitals.<sup>99</sup> The QM and MM regions interact via two mechanisms: electrostatic interactions between MM point charges and the QM wave function, and van der Waals interactions between QM and MM atoms. For the MM and QM parts of the QM/MM calculations, OPLS-AA force field<sup>100</sup> and DFT functional B3LYP<sup>101</sup> were deployed, respectively. All charges in the MM region were treated using the OPLS-AA force field. The 6-31G\* basis set was used in the interface region between the QM and MM regions. The LAV3P\*\* basis set was employed for geometry optimization: for Zn, S and P atoms, this means the Los Alamos effective core potential (ECP)<sup>102,103</sup> with all the s functions and the last p and d gaussian uncontracted; for the remaining atoms, it implies 6-31G\*\* basis set. The maximum number of iterations was set to 100 cycles and all

calculations converged before reaching this limit: the root mean squared change in density matrix elements was less than the criterion of  $5.0 \times 10^{-6}$ . B3LYP provides as good or better geometries and energies as those from correlated ab initio methods for the first-row transition metal complexes.<sup>5</sup> We therefore selected B3LYP to optimize the structures of the complexes in Step 2. In Step 4, the interaction energies were calculated by subtracting the QM/MM energy of the ligand and the receptor from the QM/MM energy of the complex for the time-averaged structures (Eq. 2).

**Molecular Dynamics Simulations** were performed using SYBYL 6.9 under isothermal/isobaric (NPT) conditions with Tripos force field.<sup>104</sup> The QM/MM-optimized bonds between the zinc-binding group (hydroxamate oxygens) of inhibitors, zinc and nitrogens of His401, His405, and His411, slightly different for each ligand, were restrained with a harmonic potential (the force constant 200, power 2) throughout the simulation. The Mulliken charges<sup>105</sup> resulting from the QM/MM optimization were used for the QM region (ligand, catalytic zinc, coordinating histidine and glutamate residues). For the rest of the protein and water, Gasteiger-Hückel charges<sup>106</sup> were used. For each system, only one set of simulations was performed with the ligand bound to the protein with a cap comprising two layers of water (TIP3P) molecules,<sup>104</sup> surrounding the complex. The water molecules were then minimized for 10,000 cycles using conjugate gradient minimization keeping the protein and ligand atom fixed to its initial positions. The outer portion of the water cap was farther than 5 Å from the ligand superposition after Step 2 and was assigned to the frozen region. Subsequently MD simulation was performed for 20 ps for the mobile water molecules, keeping the protein, ligand, and crystal water and frozen water fixed. This solvent equilibration phase was performed in order for the solvent molecule to readjust to the potential field of the ligand-receptor complex.

After the 15-ps heating phase, when the temperature of the system was raised from 0 to 300 K, the equilibration run was performed for 100 ps. Finally, the production phase was carried out at 300 K for 200 ps. The time step of the simulations was 1 fs with a cutoff of 12 Å for nonbonded interactions. The nonbonded pairs were updated every 25 fs. All residues within 5 Å of any atom in the ligand superposition after Step 2 were allowed to move freely and the remaining part of the protein and water was kept frozen. This setting was identical for all ligands. The time-averaged structures, obtained from the readings in 100 fs intervals, of the complete mobile region were collected at appropriate times. These structures were briefly minimized, to relieve the worst conflicts, using the Tripos force field with a distance-dependent dielectrics and the Powell conjugate gradient algorithm with a convergence criterion of 0.001 kcal/(mol×Å). The minimization produces structures with standard bond length and angles, with the dihedrals representing the ensemble. The time-averaged structures were shown to provide similar LIE correlations as ensemble averages.<sup>72,73</sup> The single-point QM/MM energy calculations on the time-averaged structures were used to estimate the zinc binding energies. The polar, non-polar and total solvent accessible surface area (SASA) terms were calculated using the ProsSat option in the Homology module of the Insight II modeling package.<sup>107</sup>

### Regression and Cross-Validation

The least-square fits<sup>108</sup> were based on Eq 1 and Eq 3 with the constant term. The robustness of the regression equations and their predictive abilities were probed by cross-validation. For this purpose, the fits to the potency data are generated leaving out one or more inhibitors from the calibration process. The resulting equation for each fit is used to predict the potencies of the omitted compounds. We used the leave-one-out (LOO) approach and the leave-several-out (LSO) approach, where 6 inhibitors were randomly omitted and the process was repeated 200 times. The correlations of the LOO and LSO predictions with the actual potencies were characterized by the root mean square errors (RMSE).

## Conclusions

A computational approach combining docking, QM/MM calculations, and MD simulations was developed for prediction of binding affinities of ligands to metalloproteins. The use of QM/MM energies in the ELR-type correlations was facilitated by the use of time-averaged structures from MD simulations. The application of the approach to the MMP-9 inhibition by 28 hydroxamates resulted in an excellent correlation ( $r^2 = 0.900$ ) between experimental and calculated values for all tested compounds that exhibit ~4000-fold difference in binding affinity, with the inhibition constants  $K_i$  ranging from 0.08 to 349 nM. Prediction ability of the correlation is characterized by RMSE ~ 0.3 for the  $\log K_i$  values, as compared to RMSE > 0.6 if the QM/MM term is not used. The examination of the energetic and structural results provides a basis for understanding activity differences of individual inhibitors and for their rational design. The proposed approach improves the descriptive and predictive abilities for metalloprotein ligand affinity prediction as compared to the LR approach at the expense of about a four-fold increase in the computational time.

## Acknowledgments

This work was supported in part by the NIH NCRR grants 1P20RR15566 and 1P20RR16471, as well as by the access to resources of the Computational Chemistry and Biology Network and the Center for High Performance Computing, both at the North Dakota State University.

## REFERENCES

1. Lipscomb WN, Straeter N. Recent advances in zinc enzymology. *Chem. Rev* 1996;96:2375–2433. [PubMed: 11848831]
2. Messerschmidt, A.; Huber, R.; Poulos, T.; Wieghardt, K. *Handbook of Metalloproteins*. John Wiley & Sons; 2001.
3. Messerschmidt, A.; Bode, O.; Cygler, M. *Handbook of Metalloproteins*. John Wiley & Sons; 2004.
4. Zheng YJ, Merz KM Jr. Mechanism of the human carbonic anhydrase II-catalyzed hydration of carbon dioxide. *J. Am. Chem. Soc* 1992;114:10498–10507.
5. Ryde U. Carboxylate binding modes in zinc proteins: A theoretical study. *Biophys. J* 1999;77:2777–2787. [PubMed: 10545376]
6. Dudev T, Lim C. Metal binding in proteins: The effect of the dielectric medium. *J. Phys. Chem. B* 2000;104:3692–3694.
7. Rogalewicz F, Ohanessian G, Gresh N. Interaction of neutral and zwitterionic glycine with  $Zn^{2+}$  in gas phase: Ab initio and SIBFA molecular mechanics calculations. *J. Comput. Chem* 2000;21:963–973.
8. Rulisek L, Havlas Z. Theoretical studies of metal ion selectivity. 1. DFT calculations of interaction energies of amino acid side chains with selected transition metal ions ( $Co^{2+}$ ,  $Ni^{2+}$ ,  $Cu^{2+}$ ,  $Zn^{2+}$ ,  $Cd^{2+}$ , and  $Hg^{2+}$ ). *J. Am. Chem. Soc* 2000;122:10428–10439.
9. Deerfield DW, Carter CW, Pedersen LG. Models for protein-zinc ion binding sites. II. The catalytic sites. *Int. J. Quant. Chem* 2001;83:150–165.
10. Remko M, Garaj V. Thermodynamics of binding of  $Zn^{2+}$  to carbonic anhydrase inhibitors. *Mol. Phys* 2003;101:2357–2368.
11. Koca J, Zhan CG, Rittenhouse RC, Ornstein RL. Coordination number of zinc ions in the phosphotriesterase active site by molecular dynamics and quantum mechanics. *J. Comput. Chem* 2003;24:368–378. [PubMed: 12548728]
12. Stote RH, Karplus M. Zinc binding in proteins and solution: A simple but accurate nonbonded representation. *Proteins* 1995;23:12–31. [PubMed: 8539245]
13. Hu X, Shelver WH. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction. *J. Mol. Graph. Model* 2003;22:115–126. [PubMed: 12932782]

14. Donini OA, Kollman PA. Calculation and prediction of binding free energies for the matrix metalloproteinases. *J. Med. Chem* 2000;43:4180–4188. [PubMed: 11063614]
15. Hou TJ, Guo SL, Xu XJ. Predictions of binding of a diverse set of ligands to gelatinase-A by a combination of molecular dynamics and continuum solvent models. *J. Phys. Chem. B* 2002;106:5527–5535.
16. Pang Y, Xu K, Yazal J, Prendergast FG. Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach. *Protein Sci* 2000;9:1857–1865. [PubMed: 11106157]
17. Pang YP. Novel zinc protein molecular dynamics simulations: Steps toward antiangiogenesis for cancer treatment. *J. Mol. Model* 1999;5:196–202.
18. Hoops SC, Anderson KW, Merz KM. Force field design for metalloproteins. *J. Am. Chem. Soc* 1991;113:8262–8270.
19. Hou TJ, Zhang W, Xu XJ. Binding affinities for a series of selective inhibitors of gelatinase-A using molecular dynamics with a linear interaction energy approach. *J. Phys. Chem. B* 2001;105:5304–5315.
20. Toba S, Damodaran KV, Merz KM Jr. Binding preferences of hydroxamate inhibitors of the matrix metalloproteinase human fibroblast collagenase. *J. Med. Chem* 1999;42:1225–1234. [PubMed: 10197966]
21. Vedani A. YETI: An interactive molecular mechanics program for small-molecule protein complexes. *J. Comput. Chem* 1988;9:269–280.
22. Vedani A, Huhta DW. A new force field for modeling metalloproteins. *J. Am. Chem. Soc* 1990;112:4759–4767.
23. Piquemal JP, Williams-Hubbard B, Fey N, Deeth RJ, Gresh N, Giessner-Prettre C. Inclusion of the ligand field contribution in a polarizable molecular mechanics: SIBFA-LF. *J. Comput. Chem* 2003;24:1963–1970. [PubMed: 14531050]
24. Sternberg U, Koch FT, Brauer M, Kunert M, Anders E. Molecular mechanics for zinc complexes with fluctuating atomic charges. *J. Mol. Model* 2001;7:54–64.
25. El-Yazal J, Pang YP. Novel stable configurations and tautomers of the neutral and deprotonated hydroxamic acids predicted from high-level ab initio calculations. *J. Phys. Chem. A* 1999;103:8346–8350.
26. Burton VJ, Deeth RJ, Kemp CM, Gilbert PJ. Molecular mechanics for coordination complexes: The impact of adding d-electron stabilization energies. *J. Am. Chem. Soc* 1995;117:8407–8415.
27. Deeth RJ. The ligand field molecular mechanics model and the stereoelectronic effects of d and s electrons. *Coord. Chem. Rev* 2001;212:11–34.
28. Warshel A, Levitt M. Theoretical studies of enzymic reactions: dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme. *J. Mol. Biol* 1976;103:227–249. [PubMed: 985660]
29. Singh UC, Kollmann PA. A combined ab initio quantum mechanical and molecular mechanical method for carrying out simulations on complex molecular systems: applications to the CH<sub>3</sub>Cl + Cl<sup>-</sup> exchange reaction and gas phase protonation of polyethers. *J. Comput. Chem* 1986;7:718–730.
30. Tapia O, Lluch JM, Cardenas R, Andres J. Theoretical study of solvation effects on chemical reactions. A combined quantum chemical/Monte Carlo study of the Meyer-Schuster reaction mechanism in water. *J. Am. Chem. Soc* 1989;111:829–835.
31. Field MJ, Bash PA, Karplus M. A combined quantum mechanical and molecular mechanical potential for molecular dynamics simulations. *J. Comput. Chem* 1990;11:700–733.
32. Warshel A, Karplus M. Calculation of ground and excited state potential surfaces of conjugated molecules. I. Formulation and parametrization. *J. Am. Chem. Soc* 1972;94:5612–5625.
33. Gao J, Furlani TR. Simulating solvent effects in organic chemistry: combining quantum and molecular mechanics. *IEEE Comput. Sci. Eng* 1995;2:24–33.
34. Mulholland AJ. The QM/MM approach to enzymatic reactions. *Theor. Comput. Chem* 2001;9:597–653.
35. Aqvist J, Warshel A. Simulation of enzyme reactions using valence bond force fields and other hybrid quantum/classical approaches. *Chem. Rev* 1993;93:2523–2544.


36. Raha K, Merz KM Jr. A Quantum mechanics-based scoring function: Study of zinc ion-mediated ligand binding. *J. Am. Chem. Soc* 2004;125:1020–1021. [PubMed: 14746460]
37. Kollman P. Free energy calculations: Applications to chemical and biochemical phenomena. *Chem. Rev* 1993;93:2395–2417.
38. van Gunsteren, WF. Methods for calculation of free energies and binding constants: success and problems. In: van Gunsteren, WF.; Weiner, PK., editors. *Computer Simulation of Biomolecular Systems*. Leiden: ESCOM; 1989. p. 27-59.
39. Radmer RJ, Kollman PA. Free energy calculation methods: A theoretical and empirical comparison of numerical errors and a new method for qualitative estimates of free energy changes. *J. Comput. Chem* 2003;18:902–919.
40. Srinivasan J, Cheatham TE III, Cieplak P, Kollman PA, Case DA. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. *J. Am. Chem. Soc* 1998;120:9401–9409.
41. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. *Acc. Chem. Res* 2000;33:889–897. [PubMed: 11123888]
42. Rizzo RC, Toba S, Kuntz ID. A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized Born molecular dynamics simulations. *J. Med. Chem* 2004;47:3065–3074. [PubMed: 15163188]
43. Aqvist J, Medina C, Samuelsson JE. A new method for predicting binding affinity in computer-aided drug design. *Protein Eng* 1994;7:385–391. [PubMed: 8177887]
44. Hansson T, Aqvist J. Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. *Protein Eng* 1995;8:1137–1144. [PubMed: 8819979]
45. Aqvist J. Calculation of absolute binding free energies for charged ligands and effects of long-range electrostatic interactions. *J. Comput. Chem* 1996;17:1587–1597.
46. Carlson HA, Jorgensen WL. An Extended Linear Response method for determining free energies of hydration. *J. Phys. Chem* 1995;99:10667–10673.
47. Jones-Hertzog DK, Jorgensen WL. Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a Linear Response method. *J. Med. Chem* 1997;40:1539–1549. [PubMed: 9154975]
48. Lamb ML, Tirado-Rives J, Jorgensen WL. Estimation of the binding affinities of FKBP12 inhibitors using a linear response method. *Bioorg. Med. Chem* 1999;7:851–860. [PubMed: 10400338]
49. Wang W, Wang J, Kollman PA. What determines the van der Waals coefficient beta in the LIE (linear interaction energy) method to estimate binding free energies using molecular dynamics simulations? *Proteins* 1999;34:395–402. [PubMed: 10024025]
50. Sham YY, Chu ZT, Tao H, Warshel A. Examining methods for calculations of binding free energies: LRA, LIE, PDL-D-LRA, and PDL-D/S-LRA calculations of ligands binding to an HIV protease. *Proteins* 2000;39:393–407. [PubMed: 10813821]
51. Almlof M, Brandsdal BO, Aqvist J. Binding affinity prediction with different force fields: examination of the linear interaction energy method. *J. Comput. Chem* 2004;25:1242–1254. [PubMed: 15139037]
52. Ljungberg KB, Marelius J, Musil D, Svensson P, Norden B, Åqvist J. Computational modelling of inhibitor binding to human thrombin. *Eur. J. Pharm. Sci* 2001;12:441–446. [PubMed: 11231110]
53. Hansson T, Marelius J, Aqvist J. Ligand binding affinity prediction by linear interaction energy methods. *J. Comput. Aided Mol. Des* 1998;12:27–35. [PubMed: 9570087]
54. Åqvist J, Marelius J. The linear interaction energy method for predicting ligand binding free energies. *Comb. Chem. High Throughput Screen* 2001;4:613–626. [PubMed: 11812258]
55. Åqvist J, Luzhkov VB, Brandsdal BO. Ligand binding affinities from MD simulations. *Acc. Chem. Res* 2002;35:358–365. [PubMed: 12069620]
56. Duffy EM, Jorgensen WL. Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol, and water. *J. Am. Chem. Soc* 2000;122:2878–2888.
57. Head RD, Smythe ML, Oprea TI, Waller CL, Green SM, Marshall GR. VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands. *J. Am. Chem. Soc* 1996;118:3959–3969.

58. Tokarski JS, Hopfinger AJ. Prediction of ligand-receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: Application to a set of peptidomimetic renin inhibitors. *J. Chem. Inf. Comp. Sci* 1997;37:792–811.
59. Venkatarangan P, Hopfinger AJ. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: Applications to a set of glucose analogue inhibitors of glycogen phosphorylase. *J. Med. Chem* 1999;42:2169–2179. [PubMed: 10377222]
60. Ortiz AR, Pisabarro MT, Gago F, Wade RC. Prediction of drug binding affinities by comparative binding energy analysis. *J. Med. Chem* 1995;38:2681–2691. [PubMed: 7629807]
61. Huang D, Caflisch A. Efficient evaluation of binding free energy using continuum electrostatics solvation. *J. Med. Chem* 2004;47:5791–5797. [PubMed: 15509178]
62. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. *J. Mol. Biol* 1982;161:269–288. [PubMed: 7154081]
63. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol* 1997;267:727–748. [PubMed: 9126849]
64. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. *J. Mol. Biol* 1996;261:470–489. [PubMed: 8780787]
65. Bohm HJ. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. *J. Comput. Aided Mol. Des* 1998;12:309–323. [PubMed: 9777490]
66. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. *J. Comput. Aided Mol. Des* 1997;11:425–445. [PubMed: 9385547]
67. Muegge I, Martin YC. A general and fast scoring function for protein-ligand interactions: A simplified potential approach. *J. Med. Chem* 1999;42:791–804. [PubMed: 10072678]
68. Gohlke H, Hendlich M, Klebe G. Knowledge-based scoring function to predict protein-ligand interactions. *J. Mol. Biol* 2000;295:337–356. [PubMed: 10623530]
69. Ishchenko AV, Shakhnovich EI. Small Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions. *J. Med. Chem* 2002;45:2770–2780. [PubMed: 12061879]
70. Sawa M, Kiyoi T, Kurokawa K, Kumihara H, Yamamoto M, Miyasaka T, Ito Y, Hirayama R, Inoue T, Kirii Y, Nishiwaki E, Ohmoto H, Maeda Y, Ishibushi E, Inoue Y, Yoshino K, Kondo H. New type of metalloproteinase inhibitor: Design and synthesis of new phosphonamide-based hydroxamic acids. *J. Med. Chem* 2002;45:919–929. [PubMed: 11831904]
71. Lukacova V, Zhang Y, Mackov M, Baricic P, Raha S, Calvo JA, Balaz S. Similarity of binding sites of human matrix metalloproteinases. *J. Biol. Chem* 2004;279:14194–14200. [PubMed: 14732707]
72. Zoete V, Michielin O, Karplus M. Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors. *J. Comput. Aided Mol. Des* 2003;17:861–880. [PubMed: 15124934]
73. Van Vlijmen HWT, Schaefer M, Karplus M. Improving the accuracy of protein pKa calculations: conformational averaging versus the average structure. *Proteins* 1998;33:145–158. [PubMed: 9779784]
74. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. *Nucleic Acids Res* 2000;28:235–242. [PubMed: 10592235]
75. Kramer B, Rarey M, Lengauer T. Evaluation of the FlexX incremental construction algorithm for protein-ligand docking. *Proteins* 1999;37:228–241. [PubMed: 10584068]
76. Hu X, Balaz S, Shelver WH. A practical approach to docking of zinc metalloproteinase inhibitors. *J. Mol. Graphics. Model* 2004;22:293–397.
77. Khandelwal A, Lukacova V, Kroll DM, Comez D, Raha S, Balaz S. Simulation-based predictions of binding affinities of matrix metalloproteinase inhibitors. *QSAR Comb. Sci* 2004;23:754–766.
78. El-Yazal J, Pang YP. Proton dissociation energies of zinc-coordinated hydroxamic acids and their relative affinities for zinc: Insight into design of inhibitors of zinc-containing proteinases. *J. Phys. Chem. B* 2000;104:6499–6504.


79. Browner MF, Smith WW, Castelhana AL. Matrilysin-inhibitor complexes: Common themes among metalloproteases. *Biochemistry* 1995;34:6602–6610. [PubMed: 7756291]
80. Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. *Biochemistry* 1995;34:14012–14020. [PubMed: 7577999]
81. Grams F, Reinemer P, Powers JC, Kleine T, Pieper M, Tschesche H, Huber R, Bode W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors - implications for substrate binding and rational drug design. *Eur. J. Biochem* 1995;228:830–841. [PubMed: 7737183]
82. Advanced Chemistry Development. Toronto, ON, Canada: 2001. ACD/pKa DB 4.59.
83. Johnson LL, Pavlovsky AG, Johnson AR, Janowicz JA, Man CF, Ortwine DF, Purchase CF II, White AD, Hupe DJ. A rationalization of the acidic pH dependence for stromelysin-1 (matrix metalloproteinase-3) catalysis and inhibition. *J. Biol. Chem* 2000;275:11026–11033. [PubMed: 10753905]
84. Smiesko M, Remko M. Coordination and thermodynamics of stable Zn(II) complexes in the gas phase. *J. Biomol. Struct. Dyn* 2003;20:759–770. [PubMed: 12744706]
85. Linder DP, Rodgers KR. A theoretical study of imidazole- and thiol-based zinc binding groups relevant to inhibition of metzincins. *J. Phys. Chem. B* 2004;108:13839–13849.
86. Luque I, Freire E. Structural parameterization of the binding enthalpy of small ligands. *Proteins* 2002;49:181–190. [PubMed: 12210999]
87. Katz RA, Skalka AM. The retroviral enzymes. *Ann. Rev. Biochem* 1994;63:133–173. [PubMed: 7526778]
88. Still WC, Tempczyk A, Hawley RC, Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. *J. Am. Chem. Soc* 1990;112:6127.
89. Eisenberg D, McLachlan AD. Solvation energy in protein folding and binding. *Nature* 1986;319:199–203. [PubMed: 3945310]
90. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. *Chem. Rev* 1999;99:2735–2776. [PubMed: 11749499]
91. Beckett RP, Whittaker M. Matrix Metalloproteinase Inhibitors. *Expert Opin. Ther. Pat* 1998:259–282.
92. Jacobson IC, Reddy PG, Wasserman ZR, Hardman KD, Covington MB, Arner EC, Copeland RA, Decicco CP, Magolda RL. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases. *Bioorg. Med. Chem. Lett* 1998;8:837–842. [PubMed: 9871551]
93. Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. *J. Med. Chem* 1998;41:640–649. [PubMed: 9484512]
94. O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. *J. Med. Chem* 2000;43:156–166. [PubMed: 10649971]
95. Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SMV, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. *J. Mol. Biol* 2002;319:173–181. [PubMed: 12051944]
96. Sybyl 6.91. St. Louis, MO: Tripos Inc.;
97. Jaguar 5.0. Portland, OR: Schrödinger Inc.;
98. QSite 2.5. Portland, OR: Schrödinger Inc.;
99. Murphy RB, Philipp DM, Friesner RA. A mixed quantum mechanics/molecular mechanics (QM/MM) method for large-scale modeling of chemistry in protein environments. *J. Comput. Chem* 2000;21:1442–1457.
100. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. *J. Am. Chem. Soc* 1996;118:11225–11236.

101. Becke AD. Density-functional thermochemistry. III. The role of exact exchange. *J. Chem. Phys* 1993;98:5648–5652.
102. Hay PJ, Wadt WR. Ab initio effective core potentials for molecular calculations. Potentials for the transition metal atoms scandium to mercury. *J. Chem. Phys* 1985;82:270–283.
103. Wadt WR, Hay PJ. Ab initio effective core potentials for molecular calculations. Potentials for main group elements sodium to bismuth. *J. Chem. Phys* 1985;82:284–298.
104. Clark M, Cramer RDI, van Op den Bosch N. Validation of the general purpose Tripos 5.2 force field. *J. Comput. Chem* 1989;10:982–1012.
105. Mulliken RS. Electronic population analysis on LCAO-MO [linear combination of atomic orbital-molecular orbital] molecular wave functions. I. *J. Chem. Phys* 1955;23:1833–1840.
106. Force field manual. St Louis, MO: Tripos Inc.; 2003. SYBYL 6.9; p. 164
107. Homology module. San Diego, CA: Accelrys, Inc.; Insight II.
108. Origin 6.0. Northampton, MA: Microcal Software, Inc.;







**Figure 1.** Average Mulliken charges and bond lengths (Å, in italics) for the complete set of 28 hydroxamate complexes (Table 1) after QM/MM optimization. The maximum standard deviations were 8.1 % for charges and 2.5 % for distances.




**Figure 2.** The effect of constrained zinc binding on the MD simulation of ligand **20** (Table 1) in the MMP-9 active site. Distances between catalytic zinc and, from the top, phosphorus, ring nitrogen, and chiral carbon atoms (structures in Table 1) and between hydroxamate oxygen (O2) and Glu402 oxygen in 10 fs intervals throughout the 5-ps MD simulation.




**Figure 3.** Experimental inhibition constants  $K_i$  (M) of hydroxamates (Table 1) vs MMP-9 as a linear combination of the change in the SASA ( $\text{\AA}^2$ ) caused by binding and the QM/MM interaction energy (kcal/mol) for the time-averaged structures obtained by MD simulation.




**Figure 4.** Correlations between experimental and calculated inhibition potencies of hydroxamates vs. MMP-9 as obtained by FlexX docking with the zinc binding based selection of modes in Step 1 (green), QM/MM minimization in Step 2 (blue), MD simulation with constrained zinc bonds in Step 3 (red), and by QM/MM energy calculations for the time-averaged structures from MD simulation in Step 4 (black). All correlation results are summarized in Table 2.




**Figure 5.** The binding modes of compound **22** (Table 1) in active site of MMP-9 obtained from FlexX docking (green), QM/MM optimization (blue), and MD simulation (red). The R<sub>1</sub> and R<sub>2</sub> substituents bind in S1 and S2' subsites, respectively. The time-averaged protein surface after MD simulation (Step 3) is shown in white for clarity. The imidazole rings of His401, His405, and His411, as well as catalytic zinc were included in creating the surface but are also shown in corresponding colors. The surface of the protein was z-clipped for better view.




**Figure 6.** The binding modes of compounds with longer  $R_1$  (compounds **4** – **9**) and  $R_2$  (**18** – **22**) substituents (Table 1) shown in ball and stick mode. Compounds with smaller  $R_1$  and  $R_2$  substituents follow a similar pattern. The catalytic zinc is represented as sphere. The empty pocket of the  $S2'$  subsite, created with the SiteID module of Sybyl,<sup>96</sup> is represented by transparent green space fill. The residues of the  $S2'$  and  $S1$  subsites as well as residues surrounding the empty pocket for compound **4** are shown in atom color in the capped stick mode. All structures are time-averaged structures from MD simulation (Step 3).




**Figure 7.** Stereo view of the binding modes and key interactions of isomers **1** (atom color) and **2** (purple) in MMP-9 active site (time-averaged structures after the Step 3). Compound **1** forms hydrogen bonds with Leu188 and Glu402, while compound **2** engages in hydrogen bond with Glu402 only. The hydrogen bonds are shown in dashed lines (magenta). Structures of isomers are shown in Table 1.

	$\log(1/K_i), K_i$ in M		$-\Delta < E_{vdw} >^a$ (kcal/mol)	$-\Delta < E_{el} >^a$ (kcal/mol)	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
	exp.	calc. $d$			Min	MD	Min $c$	MD $a$
	8.297	8.035	111.93	189.63	1216.74	689.95	417.06	389.34
	6.457	6.728	86.41	192.93	1177.15	489.14	324.51	311.53





	$\log(1/K_i), K_i$ in M		$-\Delta < E_{vdW} >^a$ (kcal/mol)	$-\Delta < E_{el} >^a$ (kcal/mol)	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
	exp.	calc. <sup>d</sup>			Min	MD	Min <sup>c</sup>	MD <sup>a</sup>
	8.693	8.819	107.04	174.78	1130.66	860.87	350.53	411.94
	8.182	7.803	106.40	169.62	1105.70	721.32	425.77	343.59


	$\log(1/K_i), K_i$ in M	$-\Delta < E_{vdW} > a$ (kcal/mol)		$-\Delta < E_{el} > u$ (kcal/mol)		$-\Delta < E_{QM/MM} > b$ (kcal/mol)		$-\Delta < SASA > (\text{\AA}^2)$	
		exp.	calc. <i>d</i>	95.40	155.90	Min	MD	Min <i>c</i>	MD <i>a</i>
	8.341	8.233			1140.95	520.52	437.80		


	log(1/K <sub>i</sub> ), K <sub>i</sub> in M		-Δ<E <sub>vdW</sub> > <i>a</i> (kcal/mol)	-Δ<E <sub>el</sub> > <i>u</i> (kcal/mol)	-Δ<E <sub>QM/MM</sub> > <i>b</i> (kcal/mol)		-Δ<SASA> (Å <sup>2</sup> )	
	exp.	calc. <i>d</i>			Min	MD	Min <i>c</i>	MD <i>a</i>
	8.189	8.315	121.79	192.67	723.49	736.12	370.67	404.369
	7.777	7.924	72.34	148.89	1107.33	646.02	455.69	395.52


*J Med Chem.* Author manuscript; available in PMC 2010 July 2.




	$\log(1/K_i), K_i$ in M		$-\Delta < E_{vdW} >^a$ (kcal/mol)	$-\Delta < E_{el} >^u$ (kcal/mol)	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
	exp.	calc. <sup>d</sup>			Min	MD	Min <sup>c</sup>	MD <sup>a</sup>
	8.466	8.337	127.92	239.22	1090.74	533.07	460.21	504.04
	8.197	8.322	120.93	190.55	980.36	746.42	381.41	400.46

	$\log(1/K_i), K_i$ in M	exp.	7.370		$-\Delta < E_{vdW} > a$ (kcal/mol)	88.32	$-\Delta < E_{el} > u$ (kcal/mol)	159.09	$-\Delta < E_{QM/MM} > b$ (kcal/mol)		
		calc. <i>d</i>	7.226						Min	874.43	MD
										$-\Delta < SASA > (\text{\AA}^2)$	
										Min <i>c</i>	320.68
											
<p><i>J Med Chem.</i> Author manuscript; available in PMC 2010 July 2.</p>											


	$\log(1/K_i), K_i$ in M		$-\Delta < E_{vdW} >^a$ (kcal/mol)	$-\Delta < E_{el} >^a$ (kcal/mol)	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
	exp.	calc. <sup>d</sup>			Min	MD	Min <sup>c</sup>	MD <sup>a</sup>
	7.379	7.562	103.30	179.29	1016.72	696.22	353.45	323.61
	7.285	7.253	88.67	192.33	879.98	614.65	303.00	321.47
	7.096	7.017	90.80	182.57	868.42	589.55	316.57	302.09





	$\log(1/K_i), K_i$ in M	exp.	7.493	$-\Delta < E_{vdW} > u$ (kcal/mol)	98.18	$-\Delta < E_{el} > u$ (kcal/mol)	176.21	$-\Delta < E_{QM/MM} > b$ (kcal/mol)		$-\Delta < SASA > (\text{\AA}^2)$	
		calc. <i>d</i>	7.122					Min	879.45	MD	595.82
											

	$\log(1/K_i), K_i$ in M exp.	calc. <i>d</i> 7.218	$-\Delta < E_{vdW} >^a$ (kcal/mol) 87.85	$-\Delta < E_{el} >^a$ (kcal/mol) 156.83	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
					Min	MD	Min <i>c</i>	MD <i>a</i>
					887.22	608.37	348.26	319.82
								
<i>J Med Chem</i> . Author manuscript; available in PMC 2010 July 2								





	log(1/K <sub>i</sub> ), K <sub>i</sub> in M		-Δ<E <sub>vdW</sub> > <i>a</i> (kcal/mol)	-Δ<E <sub>el</sub> > <i>u</i> (kcal/mol)	-Δ<E <sub>QM/MM</sub> > <i>b</i> (kcal/mol)		-Δ<SASA> (Å <sup>2</sup> )	
	exp.	calc. <i>d</i>			Min	MD	Min <i>c</i>	MD <i>a</i>
	7.020	7.635	95.44	183.74	982.55	696.22	334.14	333.28

	$\log(1/K_i), K_i$ in M exp. 7.228 calc. <i>d</i> 7.224	$-\Delta < E_{vdW} >^a$ (kcal/mol) 94.51	$-\Delta < E_{el} >^a$ (kcal/mol) 159.36	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
				Min	MD	Min <i>c</i>	MD <i>a</i>
				949.87	595.82	319.49	326.53
							

	$\log(1/K_i), K_i$ in M		$-\Delta < E_{vdW} > a$ (kcal/mol)	$-\Delta < E_{el} > u$ (kcal/mol)	$-\Delta < E_{QM/MM} > b$ (kcal/mol)		$-\Delta < SASA > (\text{\AA}^2)$	
	exp.	calc. <i>d</i>			Min	MD	Min <i>c</i>	MD <i>a</i>
	7.848	8.158	123.38	183.20	1307.85	551.90	459.85	471.31
	9.509	9.197	121.99	227.93	1127.44	940.95	429.04	423.94
	10.10	10.18	123.45	206.88	1121.86	834.28	451.32	604.77
	9.222	8.554	124.01	195.86	1058.55	740.15	456.49	434.23

	$\log(1/K_i), K_i$ in M		$-\Delta < E_{vdW} >^a$ (kcal/mol)	$-\Delta < E_{el} >^a$ (kcal/mol)	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
	exp.	calc. <i>d</i>			Min	MD	Min <i>c</i>	MD <i>a</i>
	10.00	9.977	137.04	224.55	1127.20	771.52	472.26	608.05
	7.417	7.675	111.28	197.02	1037.06	771.52	389.28	302.73
	7.959	8.114	0.74	0.82	1023.59	727.60	384.47	381.87
	8.420	8.026	103.83	203.22	1013.16	683.67	361.72	391.05



	log(1/K <sub>i</sub> ), K <sub>i</sub> in M		-Δ<E <sub>vdW</sub> > <i>a</i> (kcal/mol)	-Δ<E <sub>el</sub> > <i>u</i> (kcal/mol)	-Δ<E <sub>QM/MM</sub> > <i>b</i> (kcal/mol)		-Δ<SASA> (Å <sup>2</sup> )	
	exp.	calc. <i>d</i>			Min	MD	Min <i>c</i>	MD <i>a</i>
	8.947	9.193	110.63	189.12	1009.13	771.52	345.50	504.02
	8.284	8.218	132.48	237.82	879.21	740.15	428.73	389.68


	$\log(1/K_i), K_i$ in M		$-\Delta < E_{vdW} >^a$ (kcal/mol)	$-\Delta < E_{el} >^a$ (kcal/mol)	$-\Delta < E_{QM/MM} >^b$ (kcal/mol)		$-\Delta < SASA >$ ( $\text{\AA}^2$ )	
	exp.	calc. <sup>d</sup>			Min	MD	Min <sup>c</sup>	MD <sup>a</sup>
	6.500	6.081	95.55	180.16	549.68	464.73	253.08	237.38

Table 2

Correlations of inhibitory potencies with the energy and SASA terms obtained by different methods for 28 MMP-9 inhibitors. The  $\log K_i$ ,  $K_i$  in M, values were used instead of  $\Delta G_b$  in Eq. 1 and Eq. 3.

Method	Step	Eq.	$a \alpha \times 10^{-3}$ (mol/kcal)	$b \beta \times 10^{-3}$ (mol/kcal)	$c \gamma \times 10^{-3}$ (1/Å <sup>2</sup> )	$\kappa$	$r^2$	SD	F	LOO <sup>d</sup>		LSO <sup>e</sup>	
										q <sup>2</sup>	RMSE	q <sup>2</sup>	RMSE
FlexX <sup>f</sup>	1	-	69.7±63.71	-	-	-5.831±1.997	0.044	0.966	1.198	-0.079	0.989	-1.110	0.994
QM/MM Minimization	2	3	-0.420±1.190	-	12.30±3.12	-3.744±0.966	0.504	0.709	12.72	0.380	0.750	-0.457	0.808
QM/MM Minimization	2	3	-	-	11.55±2.26	-3.606±0.870	0.502	0.697	26.21	0.423	0.723	-0.278	0.751
MD	3	1	11.25±10.50	-4.090±6.010	8.380±1.240	-4.315±0.551	0.764	0.499	25.96	0.566	0.627	0.180	0.662
MD	3	1	4.630±4.060	-	8.680±1.150	-4.137±0.478	0.760	0.494	39.55	0.602	0.600	0.272	0.629
MD	3	1	-	-	9.230±1.105	4.399±0.422	0.747	0.496	76.91	0.717	0.506	0.442	0.531
QM/MM	4	3	3.592±0.580	-	7.543±0.727	-2.623±0.394	0.900	0.318	112.8	0.879	0.331	0.769	0.319

<sup>a</sup>Characterizes QM/MM interaction energy (Eq. 3) or van der Waals energy (Eq. 1).

<sup>b</sup>Characterizes electrostatic energy (Eq. 1 only).

<sup>c</sup>Characterizes the solvent accessible surface area (Eq. 1 and Eq. 3).

<sup>d</sup>Leave-one-out cross-validation.

<sup>e</sup>Leave-several-out cross-validation: random selection of 6-member test set, repeated 200 times.

<sup>f</sup>The correlation between  $\log K_i$  and the FlexX scores, with the slope  $\alpha$  and the intercept  $\kappa$ .